Strengthening Southeast Asia presence with Thailand FDA registration for MH clinical displays and accelerating the adoption of AI-powered medical platforms and innovations
- Thailand FDA registration: ASUS MH-series clinical displays advance healthcare imaging expansion across Southeast Asia
- Proven AI adoption: EndoAim gains traction in Thailand with deployments and trials across leading hospitals
- Healthcare AI ecosystem: ASUS technology connects sensing, AI, and computing to support real-time clinical decision-making
SINGAPORE, Singapore, September 8, 2026 — ASUS today announced that a range of its healthcare AI solutions will be showcased at Medical Fair Asia 2026, booth #2F07, from September 9-11 at Marina Bay Sands, Singapore. The showcase highlights the ASUS smart-healthcare portfolio — spanning clinical imaging, AI-assisted diagnostics, connected sensing, and platform-driven solutions designed for real-world clinical environments. The full event details are as follows:
Medical Fair Asia 2026 | Marina Bay Sands, Singapore
September 9-10, 2026: 10:00-18:00
September 11: 10:00-17:00
ASUS booth: #2F07
ASUS clinical displays’ Thai FDA registration strengthens Southeast Asia healthcare presence
The ASUS MH3281A, MH2741A, and MH2441A clinical displays have been officially registered with the Thailand Food and Drug Administration (Thai FDA). This registration represents an important milestone for the ASUS healthcare business and supports the continued expansion of the company’s clinical display portfolio in Thailand. It also reflects the ongoing ASUS commitment to delivering high-quality imaging solutions for healthcare professionals across Southeast Asia.
This latest registration builds upon the ASUS MH series’ established regulatory foundation in major healthcare markets worldwide. All three models are currently listed as Class I medical devices by the US FDA, registered with the Taiwan FDA, and CE marked under the European Union Medical Device Regulation (EU MDR).
Designed to support demanding medical image viewing and PACS workflows, the MH series offers a range of display configurations tailored to diverse healthcare environments. The flagship MH3281A features a 31.5-inch 8MP OLED panel for exceptional detail visibility and contrast performance, while the MH2741A and MH2441A incorporate high-resolution 3.6MP IPS panels in 27-inch and 23.8-inch formats, respectively, delivering reliable performance for everyday clinical applications.
To provide reliable and consistent image reproduction for medical image viewing, all MH series models are fully compliant with the DICOM Part 14: Grayscale Standard Display Function (GSDF). This ensures precise grayscale rendering and dependable image consistency across various clinical environments.
In addition, Anti-Glare, Low-Reflection (AGLR) technology minimizes distracting reflections, while ASUS Eye Care+ technology helps reduce visual fatigue during extended viewing sessions. Together, these features enable healthcare professionals to maintain focus on fine image details and consistent color reproduction during prolonged image viewing workflows.
Joe Hsieh, ASUS Chief Operating Officer, said: “Thailand FDA registration for our MH-series clinical displays is an important step in ASUS’s healthcare expansion across Southeast Asia. It strengthens our ability to deliver an integrated smart-healthcare portfolio—from clinical imaging to AI-assisted applications and connected sensing—built for real clinical workflows. As adoption grows in the region, we remain focused on working with hospitals and partners to deploy secure, scalable solutions that help clinicians make timely, better-informed decisions.”
EndoAim, Taiwan’s No.1 endoscopy AI solution, gains strong traction in Thailand
ASUS EndoAim, the AI-powered endoscopy solution that holds the No.1 market share in Taiwan, with over 90 healthcare institutions already using the system, is now extending that success into Thailand. Approved by the Thai FDA in 2024, EndoAim continues to gain strong commercial traction in the Thai market. The solution has already been adopted by 13 hospitals spanning leading groups such as Bangkok Hospital Group, Samitivej Hospital Group, Phyathai Hospital Group, Royal Phnom Penh H, Symphaet Hospital Group, and Saint Louis Hospital, while ongoing trials are underway in more than 25 additional hospitals, generating positive feedback and reinforcing EndoAim’s growing footprint in the region.
ASUS Healthcare AI Agent: From sensing to action
At Medical Fair Asia 2026, ASUS highlights its Healthcare AI Agent vision – moving from sensing to action to support real-time clinical decision-making. Vertically integrating server and workstation computing power allows ASUS to deliver a secure, rapidly deployable, all-in-one solution. Furthermore, ASUS connects frontline sensing devices such as Handheld Ultrasound LU800 and VivoWatch 6 to the ASUS AI Agent healthcare platform and scalable computing infrastructure. This closed-loop architecture enables continuous data capture, structuring, and integration into clinical environments – empowering AI agents to analyze patient data and support timely actions across hospitals, emergency care, and remote settings, enhancing workflow efficiency, decision support, and patient monitoring. ASUS welcomes proof-of-concept opportunities from hospitals and institutions across Southeast Asia.
Leave a Reply